文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

博茨瓦纳HIV-1 C亚型感染者中 archived rilpivirine 耐药相关突变的流行率:对 cabotegravir/rilpivirine 使用的意义

Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use.
PubMed 文献 · J Antimicrob Chemother · 2023-01-01

该研究分析了博茨瓦纳5805例HIV-1 C亚型感染者的近全长pol序列,发现 archived RPV-RAMs 总流行率为13.0%(95%CI 12%-13.9%)。未治疗组和病毒抑制组的流行率分别为10.7%和13.7%,E138A是最常见突变。作者认为监测RPV-RAMs对cabotegravir/rilpivirine的有效实施至关重要。

要点

  • 博茨瓦纳HIV-1 C亚型感染者中 archived RPV-RAMs 总流行率为13.0%。
  • 未治疗组RPV-RAMs流行率为10.7%,病毒抑制组为13.7%。
  • E138A是两组中最常见的RPV-RAM,未治疗组7.9%,抑制组9.3%。

核心结论

  • 博茨瓦纳未治疗和病毒抑制的HIV-1感染者中 archived RPV-RAMs 的流行率分别为10.7%和13.7%,最常见突变为E138A。
  • 携带E138A突变的个体可能更易在cabotegravir/rilpivirine治疗中失败,监测RPV-RAMs对该方案的有效实施至关重要。

研究设计与样本

  • 研究分析了来自博茨瓦纳的5805条近全长HIV-1 pol序列(来自proviral DNA),涵盖未治疗和病毒抑制的HIV-1 C亚型感染者。
  • RPV-RAMs根据2022 IAS-USA耐药突变列表和Stanford HIV耐药数据库定义。

主要发现

  • 总体RPV-RAMs流行率为13.0%(95%CI 12%-13.9%,757/5805)。
  • 未治疗组中137/1281(10.7%,95%CI 9.1%-12.5%)至少携带一个RPV-RAM。
  • 病毒抑制组(VL<400 copies/mL)中620/4524(13.7%,95%CI 12.7%-14.7%)至少携带一个RPV-RAM。
  • E138A在未治疗组和抑制组中均为最常见突变,流行率分别为7.9%和9.3%。
  • 其余突变(L100I、K101E、E138G、E138K、E138Q、Y181C、H221Y、M230L、A98G、V179D、G190A、G190E和M230I)流行率均低于1%。

临床怎么用

  • 作者认为,由于携带E138A突变的个体可能更易在cabotegravir/rilpivirine治疗中失败,监测RPV-RAMs对该方案在博茨瓦纳的实施至关重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Pre-existing rilpivirine resistance-associated mutations (RVP-RAMs) have been found to predict HIV-1 virological failure in those switching to long-acting injectable cabotegravir/rilpivirine. We here evaluated the prevalence of archived RPV-RAMs in a cohort of people living with HIV (PWH). METHODS: We analysed near full-length HIV-1 pol sequences from proviral DNA for the presence of RPV-RAMs, which were defined according to the 2022 IAS-USA drug resistance mutation list and Stanford HIV drug resistance database. RESULTS: RPV-RAMs were identified in 757/5805 sequences, giving a prevalence of 13.0% (95% CI 12%-13.9%). Amongst the ART-naive group, 137/1281 (10.7%, 95% CI 9.1%-12.5%) had at least one RPV-RAM. Of the 4524 PWH with viral suppression on ART (VL <400 copies/mL), 620 (13.7%, 95% CI 12.7%-14.7%) had at least one RPV-RAM. E138A was the most prevalent RPV-RAM in the ART-naive group (7.9%) and the ART-suppressed group (9.3%). The rest of the mutations observed (L100I, K101E, E138G, E138K, E138Q, Y181C, H221Y, M230L, A98G, V179D, G190A, G190E and M230I) were below a prevalence of 1%. CONCLUSIONS: RPV-RAMs were present in 10.7% of ART-naive and 13.7% of ART-suppressed PWH in Botswana. The most common RPV-RAM in both groups was E138A. Since individuals with the E138A mutation may be more likely to fail cabotegravir/rilpivirine, monitoring RPV-RAMs will be crucial for effective cabotegravir/rilpivirine implementation in this setting.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Maruapula D, Moraka NO, Bareng OT, et al. Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use. J Antimicrob Chemother. 2023. PMID: 37585352. doi:10.1093/jac/dkad258

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。